FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	1145		 10	•
Machinaton	D C	20540		

OMB APPROVAL								
OMB Number:	3235-028							

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

l	OMB APPROVAL										
l	OMB Number:	3235-0287									
l	Estimated average burden										
l	hours per response:	0.5									

1. Name and Address of Reporting Person* Stonehouse Jon P					2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [ationship of F all applicab Director	•		(s) to Issuer 10% Owi	
(Last)	(F	First)	(Middle)		BCRX]							X	Officer (gi below)	ive title		Other (sp below)	ecify
4505 EMPEROR BLVD. SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) 12/15/2020							President & CEO					
(Street) DURHAM NC 27703			27703		4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Indiv	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(\$	State)	(Zip)														
			Table I - Non	Deriva	ative	Securitie	es Acqı	uired,	Disp	osed of,	or Bene	ficially O	wned				
1. Title of Security (Instr. 3)		[2. Transaction Date Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Disposed Of				5. Amount Securities Beneficially Following F Transaction	Form (D) or (P) (D) (D) (D) (D) (D) (D) (D) (D) (D) (D		: Direct I Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								v	Amount	(A) or (D)	Price	(Instr. 3 and 4)				iiisu. 4)	
Common Stock ⁽¹⁾				12/15/	2020					134,278	A	\$4.15	918,364			D	
Common Stock ⁽¹⁾			12/15/	5/2020			S		134,278	D	\$8.32(2)	784,086			D		
			Table II - D							sed of, or onvertible			/ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		rative Expiration Date of S rities Acquired (Month/Day/Year) Und r Disposed of Der		of Securit Underlyin Derivative	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
	Geounty			Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		(1) (11130. 4)	
Emp. Stock Option (Right to Buy) ⁽¹⁾	\$4.15	12/15/2020		М			134,278	03/01	/2012	03/01/2021	Common Stock	134,278	\$0	1		D	

Explanation of Responses:

\$8,31

Emp. Stock Option

(Right to Buy)

- 1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020.
- 2. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from \$8.18 to \$8.57. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

12/15/2021

12/15/2030

3. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Α

/s/ Alane P. Barnes, by power of attorney

870,000

\$0

12/17/2020

870,000

D

** Signature of Reporting Person

Stock

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

12/15/2020

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

870,000(3)